A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis

Inclusion Criteria: * Have had a diagnosis of plaque-type psoriasis at least 6 months * Plaque-type psoriasis covering at least 10% of total body surface areas * Psoriasis area-and-severity index score of 12 or greater * Considered by treating dermatologist to be a candidate for phototherapy or systemic treatment of psoriasis * Women of childbearing potential and all men must agree to use adequate birth control measures * Have no history of latent or active tuberculosis Exclusion Criteria: * Currently have nonplaque forms of psoriasis or drug-induced psoriasis * Women who are pregnant or nursing, or men and women planning pregnancy while enrolled in the study * Patients who have a history of chronic or recurrent infectious disease or who have or have had a serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months * Patients who have or ever have had a nontuberculous mycobacterial infection or opportunistic infection * Patients known to be infected with human immunodeficiency virus, hepatitis B, or hepatitis C * Patients who have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease * Have any known malignancy or have a history of malignancy within the previous 5 years (with the exception of basal cell carcinoma of the skin that has been treated with no evidence of recurrence)